CAS 1256388-51-8
:Ledipasvir
Description:
Ledipasvir is an antiviral medication primarily used in the treatment of chronic hepatitis C virus (HCV) infection. It functions as an NS5A inhibitor, targeting a protein essential for viral replication and assembly. Ledipasvir is typically administered in combination with sofosbuvir, another antiviral agent, to enhance its efficacy and broaden the treatment spectrum. The substance is characterized by its molecular formula, which reflects its complex structure, and it exhibits a high degree of solubility in organic solvents, making it suitable for formulation in oral dosage forms. Ledipasvir has a relatively long half-life, allowing for once-daily dosing, which improves patient adherence to treatment regimens. Its pharmacokinetics are influenced by factors such as food intake, which can enhance absorption. Common side effects may include fatigue, headache, and nausea, but it is generally well-tolerated. Overall, Ledipasvir represents a significant advancement in the management of hepatitis C, contributing to high cure rates when used appropriately in clinical settings.
Formula:C49H54F2N8O6
InChI:InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1
InChI key:InChIKey=VRTWBAAJJOHBQU-KMWAZVGDSA-N
SMILES:C([C@@H](NC(OC)=O)[C@H](C)C)(=O)N1CC2(C[C@H]1C=3NC(=CN3)C=4C=C5C(=CC4)C=6C(C5(F)F)=CC(=CC6)C=7C=C8C(=CC7)N=C(N8)[C@H]9N(C([C@@H](NC(OC)=O)C(C)C)=O)[C@]%10(C[C@@]9(CC%10)[H])[H])CC2
Synonyms:- Carbamic acid, N-[(1S)-1-[[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]-, methyl ester
- Gs 5885
- Methyl[(2S)-1-{(6S)-6-[5-(9,9-Difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]-hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carba-mate
- Ledipasvir
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 9 products.
Methyl ((S)-1-((S)-6-(5-(9,9-Difluoro-7-(2-((1R,3S,4S)-2-((Methoxycarbonyl)-L-Valyl)-2-Azabicyclo[2.2.1]Heptan-3-Yl)-1H-Benzo[D]Imidazol-6-Yl)-9H-Fluoren-2-Yl)-1H-Imidazol-2-Yl)-5-Azaspiro[2.4]Heptan-
CAS:Methyl ((S)-1-((S)-6-(5-(9,9-Difluoro-7-(2-((1R,3S,4S)-2-((Methoxycarbonyl)-L-Valyl)-2-Azabicyclo[2.2.1]Heptan-3-Yl)-1H-Benzo[D]Imidazol-6-Yl)-9H-Fluoren-2-Yl)-1H-Imidazol-2-Yl)-5-Azaspiro[2.4]Heptan-Purity:98%Molecular weight:889g/molLedipasvir
CAS:<p>Ledipasvir (GS-5885) is a Hepatitis C Virus NS5A Inhibitor.</p>Formula:C49H54F2N8O6Purity:99.96%Color and Shape:SolidMolecular weight:889Ledipasvir
CAS:<p>Applications Ledipasvir is most commonly used in combination with sofosbuvir for treatment in chronic hepatitis C genotype 1 patients. It inhibits an important viral phosphoprotein, NS5A, which is involved in viral replication, assembly, and secretion.<br>References Lawitz, E., et al.: J. Hepatol., 57, 24 (2012); Afdhal, N., et al.: New England J. Med., 370, 1889 (2014)<br></p>Formula:C49H54F2N8O6Color and Shape:White To Light BeigeMolecular weight:889.00Ledipasvir
CAS:<p>Anti-viral; inhibitor of NS5A protein</p>Formula:C49H54F2N8O6Purity:Min. 98 Area-%Color and Shape:Off-White PowderMolecular weight:889.00 g/molLedipasvir Impurity A
CAS:Controlled ProductFormula:C49H54F2N8O6Color and Shape:NeatMolecular weight:889.0
